D. Tural Et Al. , "Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS," TUMOR BIOLOGY , vol.35, no.2, pp.1041-1049, 2014
Tural, D. Et Al. 2014. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. TUMOR BIOLOGY , vol.35, no.2 , 1041-1049.
Tural, D., BATUR, Ş., ERDAMAR ÇETİN, A. S., Akar, E., KEPİL, N., Mandel, N. M., ... Serdengecti, S.(2014). Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. TUMOR BIOLOGY , vol.35, no.2, 1041-1049.
Tural, Deniz Et Al. "Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS," TUMOR BIOLOGY , vol.35, no.2, 1041-1049, 2014
Tural, Deniz Et Al. "Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS." TUMOR BIOLOGY , vol.35, no.2, pp.1041-1049, 2014
Tural, D. Et Al. (2014) . "Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS." TUMOR BIOLOGY , vol.35, no.2, pp.1041-1049.
@article{article, author={Deniz Tural Et Al. }, title={Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS}, journal={TUMOR BIOLOGY}, year=2014, pages={1041-1049} }